SCHEMBL4920330

SCHEMBL4920330

NC(=O)c1ccc(O)c(NC(=O)Nc2ccccc2S)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MDM4 O15151 4/20 0.46
TP53 P04637 4/20 0.46
MDM2 Q00987 2/20 0.46
CA12 O43570 8/20 0.45
CA1 P00915 8/20 0.45
CA9 Q16790 8/20 0.45
CA2 P00918 7/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TERT O14746 1/20 0.42
TOP1 P11387 1/20 0.42
CXCR1 P25024 1/20 0.40
CXCR2 P25025 1/20 0.40
NPC1 O15118 1/20 0.40
HDAC1 Q13547 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4923902 0.88 RAB9A (0.51) TP53CA12CA1CA9CA2
SCHEMBL4925227 0.84 RAB9A (0.50) CA12CA1CA9CA2RAB9A
SCHEMBL4915647 0.81 LCK (0.50) CA12CA1CA9CA2MEN1
SCHEMBL4924988 0.78 CA12 (0.57) TP53CA12CA1CA9CA2
SCHEMBL4916824 0.77 KDM4E (0.45) MDM4TP53MDM2MEN1KMT2A
SCHEMBL4927253 0.76 CA12 (0.45) CA12CA1CA9CA2MEN1
SCHEMBL27681865 0.74 CXCR2 (0.57) CA12CA1CA9CA2MEN1
SCHEMBL4915093 0.74 CA12 (0.48) CA12CA1CA9CA2KMT2A
SCHEMBL4921362 0.74 MEN1 (0.58) TP53CA12CA1CA9CA2
SCHEMBL6113921 0.73 LCK (0.46) RAB9ASMN1; SMN2L3MBTL1TERTTOP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2008-10-30 US disclosed
EP-1796681-A2 COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF Genmedica Therapeutics SL (ES) 2007-06-20 EP disclosed
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2007-03-22 US disclosed
WO-2006013209-A2 COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF GENMEDICA THERAPEUTICS SL (ES) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 MDM4 4834/4885TP53 4175/4885MDM2 3894/4885
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 MDM4 4828/4885TP53 4132/4885MDM2 3911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.